Buch, Englisch, 623 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 2910 g
Buch, Englisch, 623 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 2910 g
Reihe: Cancer Drug Discovery and Development
ISBN: 978-1-58829-177-6
Verlag: Humana Press
Leading investigators synthesize the entire laboratory and clinical process of developing anticancer drugs to create a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials. These expert authors provide their best guidance on a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique roadmap for moving an agent to NDA submission.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Molecular Targets
Udai Banerji, Ian Judson, and Paul Workman
Preclinical Screening for New Anticancer Agents
Angelika M. Burger and Heinz-Herbert Fiebig
Mouse Models in Cancer Drug Discovery and Development
Edward A. Sausville and Melinda Hollingshead
Defining the Starting Dose: Should It Be Based on mg/kg, mg/m2, or Fixed?
Howard Gurney
Phase I Trials in Oncology: Design and Endpoints
James Cassidy
Analytical Methods: Development, Validation, and Clinical Applicability
Hans Ehrsson, Staffan Eksborg, and Jonas Bergh
Validation and Control of Bioanalytical Methods in Clinical Drug Development
H. Thomas Karnes
Clinical Pharmacology Overview
Andrew P. Beelen and Lionel D. Lewis
Pharmacokinetic Modeling
Sharyn D. Baker and Michelle A. Rudek
Pharmacodynamic Modeling
Kenneth S. Bauer and William P. Petros
Pharmacometric Knowledge-Based Oncology Drug Development
Paul J. Williams, James A. Uchizono, and Ene I. Ette
Protein Binding of Anticancer Drugs
Alex Sparreboom and Walter J. Loos
Metabolism (Non-CYP Enzymes)
Sally A. Coulthard and Alan V. Boddy
Cytochrome P450 and Anticancer Drugs
Yuichi Ando
Polymorphisms in Genes of Drug Targets and Metabolism and in DNA Repair
Jan Stoehlmacher, Syma Iqbal, and Heinz-Josef Lenz
Drug Interactions, Laurent P. Rivory
ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition
Susan E. Bates and Tito Fojo
Intrathecal Chemotherapy
Jeff Stone and Susan M. Blaney
Use of Microdialysis in Preclinical and Clinical Development of Anticancer Agents
William C. Zamboni
Regional Therapy of Cancer Using Continuous Hyperthermic Peritoneal Perfusion or Vascular Isolation and Perfusion Techniques
H. Richard Alexander, Maihgan A. Kavanagh, Steven K. Libutti, and James F. Pingpank
Isolated Lung Perfusion for the Treatment of Inoperable Pulmonary Malignancies
David S. Schrump
Pharmacokinetics of Isolated Lung Perfusion with Antitumor Agents
Suoping Zhai
Central Nervous System Malignancy and Clinical Pharmacology
Steve Y. Cho and Howard A. Fine
Pharmacokinetics of Anticancer Drugs in Children
Lisa C. Iacono, P. Kellie Turner, and Clinton F. Stewart
Clinical Pharmacokinetics in the Elderly
Patricia W. Slattum and Jürgen Venitz
The Combination of Angiogenesis Inhibitors and Radiotherapy for the Treatment of Primary Tumors
Kevin Camphausen and Cynthia Ménard
Gene Therapy for the Treatment of Cancer
H. Trent Spencer and Jacques Galipeau
Vaccines for the Treatment of Cancer
Philip M. Arlen, James Gulley, Lauretta Odogwu, and John L. Marshall
Pharmacokinetics of Antibodies and Immunotoxins in Mice and Humans
Victor Ghetie, E. Sally Ward, and Ellen S. Vitetta
Pharmacokinetics of Biologicals
Håkan Mellstedt, Jan-Erik Frödin, and Anders Österborg
Exposure-Response Relationship of Anticancer Agents: A Clinical Pharmacology and Biopharmaceutics Regulatory Perspective
Atiqur Rahman
Identifying Agents to Test in Phase III Trials
Thomas G. Roberts Jr., Thomas J. Lynch Jr., and Bruce A. Chabner
Clinical Trial Designs for Approval of New Anticancer Agents: A Clinical Science
Daniel D. Von Hoff
Pharmacogenetic Counseling
Jill M. Kolesar
Index
